Back
Speaker illustration

Doctor Arthur Mader

VIVIT Institute, Feldkirch (Austria)

Member of:

European Society of Cardiology
Heart Failure Association

Presentations

Three decades of lipid-lowering therapy in type 2 diabetic patients with angiographically proven stable coronary artery disease

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Medical and percutaneous treatment of coronary artery disease

Access
Like
Thumbnail

Cystatin C predicts cardiovascular events in patients with coronary artery disease both among patients with and among those without type 2 diabetes

Event: ESC Congress 2024

Topic: Biomarkers

Session: Novel biomarkers for cardiovascular risk prediction

Access
Like
Thumbnail

Remnant cholesterol predicts major cardiovascular events in coronary artery disease patients with NAFLD

Event: ESC Congress 2024

Topic: Lipids

Session: Lipoproteins and cardiovascular risk

Access
Like
Thumbnail

The ceramide-based Coronary Event Risk Test (CERT) predicts cardiovascular mortality in cardiovascular disease patients with type 2 diabetes mellitus as well as in those without diabetes

Event: ESC Congress 2019

Topic: Biomarkers

Session: Diabetes and the heart

Access
Like
Thumbnail

Serum ceramides and type 2 diabetes are mutually independent predictors of cardiovascular events in patients with peripheral artery disease

Event: ESC Congress 2019

Topic: Biomarkers

Session: Vascular disease

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources